Nejvíce citovaný článek - PubMed ID 26729443
The current study assessed the performance of the fully automated RT-PCR-based Idylla™ GeneFusion Assay, which simultaneously covers the advanced non-small cell lung carcinoma (aNSCLC) actionable ALK, ROS1, RET, and MET exon 14 rearrangements, in a routine clinical setting involving 12 European clinical centers. The Idylla™ GeneFusion Assay detects fusions using fusion-specific as well as expression imbalance detection, the latter enabling detection of uncommon fusions not covered by fusion-specific assays. In total, 326 archival aNSCLC formalin-fixed paraffin-embedded (FFPE) samples were included of which 44% were resected specimen, 46% tissue biopsies, and 9% cytological specimen. With a total of 179 biomarker-positive cases (i.e., 85 ALK, 33 ROS1, 20 RET fusions and 41 MET exon 14 skipping), this is one of the largest fusion-positive datasets ever tested. The results of the Idylla™ GeneFusion Assay were compared with earlier results of routine reference technologies including fluorescence in situ hybridization, immunohistochemistry, reverse-transcription polymerase chain reaction, and next-generation sequencing, establishing a high sensitivity/specificity of 96.1%/99.6% for ALK, 96.7%/99.0% for ROS1, 100%/99.3% for RET fusion, and 92.5%/99.6% for MET exon 14 skipping, and a low failure rate (0.9%). The Idylla™ GeneFusion Assay was found to be a reliable, sensitive, and specific tool for routine detection of ALK, ROS1, RET fusions and MET exon 14 skipping. Given its short turnaround time of about 3 h, it is a time-efficient upfront screening tool in FFPE samples, supporting rapid clinical decision making. Moreover, expression-imbalance-based detection of potentially novel fusions may be easily verified with other routine technologies without delaying treatment initiation.
- Klíčová slova
- ALK fusion, MET exon 14 skipping, RET fusion, ROS1 fusion, Idylla, NSCLC,
- MeSH
- anaplastická lymfomová kináza * genetika MeSH
- exony * genetika MeSH
- fúzní onkogenní proteiny * genetika MeSH
- genová přestavba MeSH
- hybridizace in situ fluorescenční metody MeSH
- lidé MeSH
- multiplexová polymerázová řetězová reakce MeSH
- nádorové biomarkery genetika analýza MeSH
- nádory plic * genetika patologie MeSH
- nemalobuněčný karcinom plic * genetika patologie MeSH
- protoonkogenní proteiny c-met * genetika MeSH
- protoonkogenní proteiny c-ret * genetika MeSH
- protoonkogenní proteiny * genetika MeSH
- tyrosinkinasy * genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- hodnotící studie MeSH
- multicentrická studie MeSH
- Názvy látek
- ALK protein, human MeSH Prohlížeč
- anaplastická lymfomová kináza * MeSH
- fúzní onkogenní proteiny * MeSH
- MET protein, human MeSH Prohlížeč
- nádorové biomarkery MeSH
- protoonkogenní proteiny c-met * MeSH
- protoonkogenní proteiny c-ret * MeSH
- protoonkogenní proteiny * MeSH
- RET protein, human MeSH Prohlížeč
- ROS1 protein, human MeSH Prohlížeč
- tyrosinkinasy * MeSH
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
- Klíčová slova
- Europe, Non-small cell lung cancer, Predictive biomarker testing, Targeted therapy,
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: The MET inhibitor tepotinib demonstrated durable clinical activity in patients with advanced MET exon 14 (METex14) skipping NSCLC. We report detailed analyses of adverse events of clinical interest (AECIs) in VISION, including edema, a class effect of MET inhibitors. PATIENTS AND METHODS: Incidence, management, and time to first onset/resolution were analyzed for all-cause AECIs, according to composite categories (edema, hypoalbuminemia, creatinine increase, and ALT/AST increase) or individual preferred terms (pleural effusion, nausea, diarrhea, and vomiting), for patients with METex14 skipping NSCLC in the phase II VISION trial. RESULTS: Of 255 patients analyzed (median age: 72 years), edema, the most common AECI, was reported in 69.8% (grade 3, 9.4%; grade 4, 0%). Median time to first edema onset was 7.9 weeks (range: 0.1-58.3). Edema was manageable with supportive measures, dose reduction (18.8%), and/or treatment interruption (23.1%), and rarely prompted discontinuation (4.3%). Other AECIs were also manageable and predominantly mild/moderate: hypoalbuminemia, 23.9% (grade 3, 5.5%); pleural effusion, 13.3% (grade ≥ 3, 5.1%); creatinine increase, 25.9% (grade 3, 0.4%); nausea, 26.7% (grade 3, 0.8%), diarrhea, 26.3% (grade 3, 0.4%), vomiting 12.9% (grade 3, 1.2%), and ALT/AST increase, 12.2% (grade ≥ 3, 3.1%). GI AEs typically occurred early and resolved in the first weeks. CONCLUSION: Tepotinib was well tolerated in the largest trial of a MET inhibitor in METex14 skipping NSCLC. The most frequent AEs were largely mild/moderate and manageable with supportive measures and/or dose reduction/interruption, and caused few withdrawals in this elderly population.
- Klíčová slova
- Adverse event, Edema, MET inhibitor, Nausea, Non–small cell lung cancer,
- MeSH
- edém chemicky indukované farmakoterapie MeSH
- exony genetika MeSH
- hypoalbuminemie farmakoterapie MeSH
- inhibitory proteinkinas * škodlivé účinky MeSH
- klinické zkoušky, fáze II jako téma MeSH
- kreatinin terapeutické užití MeSH
- lidé MeSH
- mutace MeSH
- nádory plic * farmakoterapie genetika MeSH
- nauzea chemicky indukované MeSH
- nemalobuněčný karcinom plic * farmakoterapie genetika MeSH
- piperidiny škodlivé účinky MeSH
- pleurální výpotek MeSH
- průjem MeSH
- pyridaziny škodlivé účinky MeSH
- pyrimidiny škodlivé účinky MeSH
- senioři MeSH
- zvracení chemicky indukované MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- inhibitory proteinkinas * MeSH
- kreatinin MeSH
- piperidiny MeSH
- pyridaziny MeSH
- pyrimidiny MeSH
- tepotinib MeSH Prohlížeč